Amgen (AMGN) Equity Average (2009 - 2026)

Amgen (AMGN) has reported Equity Average for 18 consecutive years, with $8.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Equity Average rose 47.7% year-over-year to $8.9 billion; the TTM figure through Mar 2026 stood at $8.9 billion (up 47.7% YoY), while the FY2025 annual figure was $7.3 billion, up 20.03% from the prior year.
• Equity Average came in at $8.9 billion for Q1 2026 at Amgen, down from $9.1 billion in the prior quarter.
• The five-year high for Equity Average was $9.1 billion in Q4 2025, with the low at $1.7 billion in Q2 2022.
• Average Equity Average over 5 years is $5.9 billion, with a median of $6.1 billion recorded in 2023.
• Across the five-year window, Equity Average plunged 81.03% in 2022 and jumped 263.69% in 2023, its largest moves.
• Year by year, Equity Average stood at $3.7 billion in 2022, then jumped by 89.88% to $6.9 billion in 2023, then slipped by 3.49% to $6.7 billion in 2024, then jumped by 36.35% to $9.1 billion in 2025, then decreased by 2.35% to $8.9 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $8.9 billion, $9.1 billion, and $8.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.